NcXHF

SULLIVAN ET AL
NRAS-mutant melanoma: early encouraging clinical activity. J Clin
Oncol. 2014;32:5s (suppl; abstr 9009).
96. Chaudhury TK, Lerner MP, Nordquist RE. Angiogenesis by human
melanoma and breast cancer cells. Cancer Lett. 1980;11:43-49.
97. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor
responsible for angiogenesis. J Exp Med. 1971;133:275-288.
98. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin,
weekly paclitaxel, and biweekly bevacizumab in patients with unresectable
stage IV melanoma: a North Central Cancer Treatment Group
study, N047A. Cancer. 2009;115:119-127.
99. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II
study evaluating the activity of bevacizumab in combination with carboplatin
plus paclitaxel in patients with previously untreated advanced
melanoma. J Clin Oncol. 2012;30:34-41.
100. von Moos R, Seifert B, Simcock M, et al. First-line temozolomide combined
with bevacizumab in metastatic melanoma: a multicentre phase
II trial (SAKK 50/07). Ann Oncology. 2012;23:531-536.
101. Yap TA, Gerlinger M, Futreal PA, et al. Intratumor heterogeneity: seeing
the wood for the trees. Sci Transl Med. 2012;4:127ps10.
102. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity
and branched evolution revealed by multiregion sequencing. N Engl
J Med. 2012;366:883-892.
103. Roesch A. Tumor heterogeneity and plasticity as elusive drivers for resistance
to MAPK pathway inhibition in melanoma. Oncogene. Epub 2014 Aug 11.
104. Frei III E, Eder J. Principles of Dose, Schedule, and Combination Therapy.
In: Kufe D, Pollock R, Weichselbaum R, et al. (eds). Holland-Frei Cancer
Medicine. 6th ed. Hamilton, Ontario: BC Decker; 2003; chapter 44.
105. LoRusso PM, Canetta R, Wagner JA, et al. Accelerating cancer therapy
development: the importance of combination strategies and collaboration.
Summary of an Institute of Medicine workshop. Clin Cancer
Res. 2012;18:6101-6109.
106. Spagnolo F, Ghiorzo P, Orgiano L, et al. BRAF-mutant melanoma:
treatment approaches, resistance mechanisms, and diagnostic strategies.
Onco Targets Ther. 2015;8:157-168.
107. Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination
for BRAF-mutant metastatic melanoma. Clin Cancer Res.
2014;20:2035-2043.
108. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor
DNA in early- and late-stage human malignancies. Sci Transl
Med. 2014;6:224ra24.
109. Institute of Medicine. Facilitating collaborations to develop combination
investigational cancer therapies: Workshop summary. Washington
DC: The National Academies Press; 2011.
110. Institute of Medicine. Extending the spectrum of precompetitive collaboration
in oncology research: Workshop summary. Washington
DC: The National Academies Press; 2010.
111. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine
versus placebo plus dacarbazine as fırst-line treatment for BRAFmutant
metastatic melanoma: a phase 2 double-blind randomised
study. Lancet Oncol. 2013;14:733-740.
186 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook